Extensive Stage Small-Cell Lung Cancer

EP. 1: Current Frontline Management of Small Cell Lung Cancer

December 17th 2019

EP. 2: Small Cell Lung Cancer: Interpreting Data From IMpower133

December 17th 2019

EP. 3: Results From the CASPIAN Trial in SCLC

December 17th 2019

EP. 4: Frontline I-O Strategies in SCLC: Practical Implications

December 17th 2019

EP. 5: I-O Strategies in Relapsed/Refractory SCLC

December 17th 2019

EP. 6: Small Cell Lung Cancer: Future Directions in Care

December 17th 2019

EP. 7: The Initial Approach to SCLC Treatment

December 17th 2019

EP. 8: SCLC Therapy: First-line Options Prior to Immunotherapy

December 17th 2019

EP. 9: Checkpoint Inhibitors in Second and Third-line

December 17th 2019

EP. 10: Negative I/O Trials: CheckMate331 and CheckMate 451

December 17th 2019

EP. 11: Immunotherapy Toxicity Profile

December 17th 2019

EP. 12: First-line Immunotherapy: IMPower133 Regimen

December 17th 2019

EP. 13: Frontline Therapy Approaches for Small Cell Lung Cancer

December 17th 2019

EP. 14: Immunotherapy in Relapsed-Refractory SCLC

December 17th 2019

EP. 15: The CASPIAN Trial in Extensive-Stage SCLC

December 17th 2019

EP. 16: The ADRIATIC Trial in Limited-Stage SCLC

December 17th 2019

EP. 17: Frontline and R/R Therapy and PD-L1 Targeted Therapy for SCLC

December 17th 2019

EP. 18: Emerging Therapies for Extensive Stage SCLC and CASPIAN Trial

December 17th 2019

EP. 19: Novel Agents for R/R and the Future of Extensive Stage SCLC

December 17th 2019

EP. 20: I/O Combination Regimens & the Importance of Biomarkers

December 17th 2019

NEXT PAGE
PREVIOUS PAGE